Levels of Squamous Cell Carcinoma Antigen and Interleukin-6 as Biomarkers in NSCLC Patients

Lydia Arieta (Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital, Medan, 20155, Indonesia)
Noni Novisari Soeroso (Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital, Medan, 20155, Indonesia)
Setia Putra Tarigan (Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital, Medan, 20155, Indonesia)
Putri Chairani Eyanoer (Department of Community and Preventive Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, 20155, Indonesia)

Sumatera Medical Journal
Vol. 8 No. 2 (2025): Sumatera Medical Journal (SUMEJ)

Background: Squamous Cell Carcinoma Antigen (SCC-Ag) and Interleukin-6 (IL‐6) has been widely used for monitoring Non-Small Cell Lung Cancer (NSCLC). Objective: This concentration also known to be higher in Non Small Cell Lung Cancer. Methods: This research used descriptive study among NSCLC patients. Blood sampling was used with serum. ELISA platform was used to rate SCC-Ag and IL-6 serum. Results: From 20 samples NSCLC, we found 20 males (100%), active smokers (80%). From histology type, Adenocarcinoma 12 cases (60%). The most of subjects were in stage IVA (70%). The Squamous Cell Carcinoma Antigen levels of NSCLC patients showed that as many as 20 samples (100%) were within normal limits and did not show an increased. Conclusion: Levels of IL-6 increased as many as 15 samples (75%), and IL-6 levels were still within the normal range sample (25%). Tumor marker are not meant to detect marker growth, but only as a marker that found in lung cancer,but IL-6 as the one of the pro-inflammation cytokines that shows an increased in patients NSCLC.